Free Trial
→ Bezos… DOOMED (From Paradigm Press) (Ad)tc pixel
NASDAQ:CLRB

Cellectar Biosciences Q3 2026 Earnings Date & Estimates

Cellectar Biosciences logo
$1.19 +0.01 (+0.85%)
Closing price 10/15/2026 04:00 PM Eastern
Extended Trading
$1.21 +0.02 (+1.68%)
As of 04:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cellectar Biosciences is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. The conference call is scheduled for November 13, 2026 at 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Cellectar Biosciences in Q3 2026

Cellectar Biosciences is expected to post earnings of -$0.5565 per share on revenue of $17.00 million. In the same quarter a year earlier Cellectar Biosciences reported -$1.41 per share. Cellectar Biosciences last reported on August 13, 2026, posting -$0.57 per share and missing the -$0.52 consensus estimate. Cellectar Biosciences has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.5565
Expected Revenue
$17.00 million
Prior-Year EPS
-$1.41

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.57 (Missed by -$0.05)
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Cellectar Biosciences Q3 2026 Earnings FAQ

Cellectar Biosciences (NASDAQ:CLRB) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Cellectar Biosciences' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Cellectar Biosciences to post earnings of -$0.5565 per share for Q3 2026.

The consensus revenue estimate for Cellectar Biosciences is $17.00 million for Q3 2026.

Cellectar Biosciences' next earnings date is estimated for Thursday, October 29, 2026. MarketBeat tracks confirmed and estimated earnings dates for Cellectar Biosciences on the company's earnings history page.

Cellectar Biosciences Earnings Headlines

Cellectar Biosciences Eyes 2027 FDA Filing For Iopofosine In Waldenström Patients
October 15 at 1:32 PM  |  rttnews.comhttps://www.rttnews.com/3699380/cellectar-biosciences-eyes-2027-fda-filing-for-iopofosine-in-waldenstr-m-patients.aspx
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at ...
October 15 at 8:32 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/cellectar-biosciences-presents-compelling-efficacy-110000167.html
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
October 16 at 1:00 AM  |  Stansberry Research (Ad)
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
October 15 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/15/3381487/29076/en/cellectar-biosciences-presents-compelling-efficacy-data-from-phase-2b-clover-wam-subset-analysis-of-iopofosine-i-131-in-patients-relapsed-refractory-to-btk-inhibitor-therapy-at-the.html
Cellectar Biosciences (NASDAQ:CLRB) Share Price Breaks Below 50-Day Moving Average - What's Next?
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31090826
Cellectar's Iopofosine I 131 Shows Positive Data In Waldenström Macroglobulinemia
September 29, 2026  |  rttnews.comhttps://www.rttnews.com/3694760/cellectar-s-iopofosine-i-131-shows-positive-data-in-waldenstr-m-macroglobulinemia.aspx
See More Cellectar Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cellectar Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cellectar Biosciences and other key companies, straight to your email.

About Cellectar Biosciences

Cellectar Biosciences (NASDAQ:CLRB) is a clinical-stage biotechnology company focused on developing targeted radiopharmaceuticals for the treatment and diagnosis of cancer. The company’s technology platform is based on phospholipid ether analogs, which are designed to preferentially accumulate in tumor cells and can be linked to radioactive isotopes for targeted imaging or therapy.

Cellectar’s lead product candidate is iopofosine I 131, also known as CLR 131, a targeted radiotherapeutic being developed for cancers including relapsed or refractory multiple myeloma. The company has also investigated its platform in other hematologic malignancies and solid tumors, including neuroblastoma. Its development programs are intended to deliver radiation directly to cancer cells while limiting exposure to surrounding healthy tissue.

Cellectar Biosciences is based in Madison, Wisconsin, and has historically operated as a development-stage company whose activities center on clinical research, regulatory development and potential commercialization of its radiopharmaceutical pipeline. The company’s programs have received regulatory designations for certain cancer indications, although its products remain subject to clinical and regulatory review before they can be broadly marketed.

View Cellectar Biosciences Profile
Earnings Tools